Why VA coverage is structurally different
Most GLP-1 coverage advice online is written for commercial insurance, and applying it here wastes time. The differences are not cosmetic.
| Commercial plan | VA | |
|---|---|---|
| What it is | An insurer paying claims | An integrated health system that also dispenses |
| Drug list | Plan formulary, varies by employer | VA National Formulary |
| Access gate | Prior authorization | Criteria for use |
| If refused | Internal appeal, then binding external review | Non-formulary request with clinical justification |
| Who prescribes | Any licensed prescriber | VA provider, or community care under VA authorization |
| Savings card | Allowed | Barred — federal program |
The practical consequence: if you are searching for how to appeal a GLP-1 denial and landing on pages about ERISA and external review, those do not describe your situation. The route here runs through your VA provider and VA processes.
The savings card does not apply to you
The VA is a federal healthcare program, and federal anti-kickback law (42 U.S.C. § 1320a-7b) bars manufacturers from paying down copays for anyone enrolled in one. Every GLP-1 savings card says so in its terms. Worth knowing before you fill in the application — it is heavily advertised and the restriction is in the fine print.
The good news is that you are likely better off anyway. VA medication copays are tiered and annually capped, and many Veterans are exempt from medication copays entirely depending on service-connected disability rating, income, and other qualifying categories. That structure generally beats any commercial copay or cash program, which is why establishing VA coverage is worth more effort than price-shopping elsewhere.
Coverage follows the indication here too
Access is more established for type 2 diabetes than for weight management, which mirrors payers generally. The distinction to hold onto:
- Ozempic and Mounjaro are FDA-approved for type 2 diabetes.
- Wegovy and Zepbound are approved for chronic weight management — and each carries a second indication that is not a weight-loss use: Wegovy for cardiovascular risk reduction in adults with established heart disease plus overweight or obesity, Zepbound for moderate-to-severe obstructive sleep apnea in obesity.
Those second indications are separate clinical routes, documented differently. Whether one applies depends on your diagnosis — a question for your VA provider rather than a framing to adopt.
Where MOVE! fits
The VA runs MOVE!, its weight management program, and lifestyle intervention is generally part of how the VA approaches obesity care. Criteria for use for weight-management medications commonly reference documented participation in a structured program.
The useful reframe: rather than treating that as a hurdle placed in front of medication, it is usually part of the path — and documented participation is exactly the kind of evidence that supports a request. If you are considering asking about a GLP-1, asking about MOVE! in the same conversation is reasonable.
If it is not covered: the non-formulary request
Separate two situations, because they have different remedies:
- You do not meet criteria for use. Similar to a commercial criteria denial — the fix is usually documentation. Baseline weight and BMI, qualifying conditions, and what has already been tried, with dates.
- The drug is non-formulary. The route is a non-formulary request submitted by your VA provider with clinical justification for why formulary alternatives are unsuitable for you.
Both run through your VA provider. The general principles of building a case still apply — get the reason in writing, match the response to the reason — even though the machinery differs. General mechanics: appealing a GLP-1 denial.
Filling outside the VA
Community care exists where VA cannot provide timely care, but it runs under VA authorization rules rather than as free choice. Filling outside VA without that process generally means paying yourself.
If that is where you end up, the realistic cash figures are the manufacturer self-pay programs — Zepbound from $299/mo (2.5 mg)[zepbound], Wegovy about $349/month at maintenance, the oral Wegovy pill from around $149 — plus patient assistance if you qualify. Those cash programs are open to you; only the copay card is not.
Every cash route in order · patient assistance · TRICARE coverage
The VA National Formulary and its criteria for use are updated documents, and eligibility depends on your enrollment, priority group and clinical situation. This describes how the system works as of 2026-07-19 — it is information, not coverage advice. Confirm current details through the VA Formulary Advisor and your VA care team.